Brookline Capital Markets Reiterates Buy Rating, $15 Price Target on MEI Pharma (MEIP), Sees "Upside to Longer-Term Outlook" from ME-344 Contributions
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $15.00 price target on MEI Pharma (NASDAQ: MEIP) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE